EMA/712443/2013

European Medicines Agency decision

P/0313/2013

of 19 December 2013

on the agreement of a paediatric investigation plan for Heterologous Human Adult Liver-derived Progenitor Cells (HHALPC) (EMEA-001155-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision

P/0313/2013

of 19 December 2013

on the agreement of a paediatric investigation plan for Heterologous Human Adult Liver-derived Progenitor Cells (HHALPC) (EMEA-001155-PIP01-11) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the application submitted by Promethera Biosciences on 10 May 2011 under Article 16(1) of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 November 2013, in accordance with Article 18 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

A paediatric investigation plan for Heterologous Human Adult Liver-derived Progenitor Cells (HHALPC), cell suspension for infusion, intravenous use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

This decision is addressed to Promethera Biosciences, Rue Granbonpré, 11, 1435 - Mont Saint Guibert, Belgium.

Done at London, 19 December 2013

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/518599/2013

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan

EMEA-001155-PIP01-11

Scope of the application

Active substance(s):

Heterologous Human Adult Liver-derived Progenitor Cells (HHALPC)

Condition(s):

Treatment of urea cycle disorders

Treatment of Crigler-Najjar syndrome

Pharmaceutical form(s):

Cell suspension for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Promethera Biosciences

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Promethera Biosciences submitted for agreement to the European Medicines Agency on 10 May 2011 an application for a paediatric investigation plan for the above mentioned medicinal product.

The procedure started on 15 June 2011.

Supplementary information was provided by the applicant on 13 August 2013. The applicant proposed modifications to the paediatric investigation plan.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation;

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 8 November 2013

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: treatment of urea cycle disorders

2.1.1. Indication(s) targeted by the PIP

Treatment of urea cycle disorders.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Cell suspension for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality	Total number of quality measures	Measure 1 To restrict the concentration of DMSO in the final product for paediatric patients.
Non-clinical	Total number of measures	Measure 2 Biodistribution, Toxicity and Tumorigenicity study (GLP) in NOD SCID gamma mice / 6 and 8 weeks.
Clinical	Total number of measures	Measure 3 Prospective multi-centre observational study with a retrospective part in children from birth to less than 18 years of age with urea cycle disorders or Crigler-Najjar syndrome. Measure 4 Dose escalation/safety study in in children from birth to less than 18 years of age with urea cycle disorders or Crigler-Najjar syndrome. Measure 5 Efficacy/safety study in children from birth to less than 18 years with urea cycle disorders.

2.2. Condition: treatment of Crigler-Najjar syndrome

2.2.1. Indication(s) targeted by the PIP

Treatment of Crigler-Najjar syndrome

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Cell suspension for infusion

2.2.4. Measures

Area	Number of measures	Description
Quality	Total number of quality measures	Measure 1 To restrict the concentration of DMSO in the final product for paediatric patients.
Non-clinical	Total number of measures	Measure 2 Biodistribution, Toxicity and Tumorigenicity study (GLP) in NOD SCID gamma mice / 6 and 8 weeks.
Clinical	Total number of measures	Measure 3 Prospective multi-center observational study with a retrospective part in children from birth to less than 18 years of age with urea cycle disorders or Crigler-Najjar syndrome. Measure 4 Dose escalation/safety study in in children from birth to less than 18 years of age with urea cycle disorders or Crigler-Najjar syndrome. Measure 6 Efficacy/safety study in children from birth to less than 18 years with Crigler-Najjar syndrome.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By June 2018
Deferral for one or more measures contained in the paediatric investigation plan:	No